pyrroles has been researched along with Coronary Artery Disease in 330 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.21) | 18.2507 |
| 2000's | 182 (55.15) | 29.6817 |
| 2010's | 144 (43.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arefieva, TI; Filatova, AY; Masenko, VP; Noeva, EA; Osokina, AK; Potekhina, AV; Provatorov, SI; Romasov, IV; Samko, AN; Shchinova, AM; Shlevkova, GV; Zharova, EA | 1 |
| Bonello, L; Laine, M; Paganelli, F | 1 |
| Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Cheng, C; de Boer, SP; de Jong, R; de Winter, RJ; den Dekker, WK; den Heijer, P; Duckers, HJ; Houtgraaf, JH; Ligtenberg, E; Rowland, SM; Serruys, PW; Zijlstra, F | 1 |
| Hashimoto, Y; Matsue, Y; Matsumura, A; Suzuki, M; Yoshida, M | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Biwa, T; Kurogi, K; Matsui, K; Nakamura, S; Ogawa, H; Sakamoto, K; Sugiyama, S; Tayama, S | 1 |
| Chang, HJ; Cho, IJ; Chung, N; Ha, JW; Hong, GR; Hong, SJ; Kang, DR; Park, S; Shim, CY; Shin, S | 1 |
| Abaci, O; Coskun, U; Kilickesmez, KO; Kocas, C; Oktay, V; Yigit, Z; Yildiz, A; Yildiz, CE | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 4 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Itoh, T; Nakamura, M; Satoh, M; Tabuchi, T | 2 |
| de Graaf, MA; Jukema, JW | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Chen, Q; Cong, HL; Cui, R; Gao, J; Liu, T; Liu, Y; Mao, YM; Zhang, N | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Chen, Q; Cong, HL; Cui, RZ; Gao, J; Liu, T; Liu, Y; Mao, YM; Zhang, N | 1 |
| Takagi, H; Umemoto, T | 2 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 2 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 2 |
| Barkate, H; Dalal, J; Dani, S; Hiremath, MS; Jindal, C; Kahali, D; Kaul, U; Ramchandran, P; Rane, R; Varma, J | 1 |
| Barter, PJ; DeMicco, DA; Messig, M; Ong, KL; Rye, KA; Waters, DD | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 1 |
| Deng, B; Li, J; Lv, LX; Xie, NZ; Zhang, L; Zheng, LQ | 1 |
| Guo, YL; Li, JJ; Li, S; Li, XL; Xu, RX | 1 |
| Gamou, T; Hayashi, K; Higashikata, T; Hirase, H; Ino, H; Kanaya, H; Katsuda, S; Kawashiri, MA; Konno, T; Michishita, I; Miwa, K; Mizuno, S; Nagase, K; Namura, M; Nitta, Y; Okeie, K; Sakata, K; Tada, H; Terashima, M; Uchiyama, K; Ueda, K; Yamagishi, M | 1 |
| Liu, X; Qu, Y; Shen, H; Xia, J | 1 |
| Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X | 1 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Asrar Ul Haq, M; Mutha, V; Rudd, N; Subiakto, I; Van Gaal, WJ | 1 |
| Campos, CM; Garcia-Garcia, HM; Serruys, PW | 1 |
| Akagi, H; Akasaka, T; Imanishi, T; Ino, Y; Kitabata, H; Komukai, K; Kubo, T; Kumiko, H; Matsuo, Y; Okumoto, Y; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Takarada, S; Tanaka, A; Tanimoto, T; Ueno, S; Yamaguchi, T; Yamano, T | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Gu, GL; Xu, XL; Yang, QY; Zeng, RL | 1 |
| Betteridge, J; Bittner, VA; Fayyad, R; Hsue, PY; Laskey, R; Waters, DD; Wenger, NK | 1 |
| Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC | 1 |
| Crea, F; Niccoli, G | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Hokimoto, S; Kaikita, K; Ogawa, H; Shimomura, H; Sugiyama, S; Tsujita, K; Yamanaga, K | 4 |
| Koh, KK | 1 |
| Goldstein, MR; Mascitelli, L | 1 |
| Lloyd-Jones, D; Smith, S; Stone, NJ | 1 |
| Chapman, J; Giral, P; Hansel, B | 1 |
| Bedogni, F; Montone, RA; Testa, L | 1 |
| Abdel-Wahab, M; Richardt, G | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Ikeda, S; Koga, S; Kohno, S; Miyahara, Y; Oka, H | 1 |
| Feng, M; Li, L; Meng, X; Qie, L; Wang, Y; Zhong, M | 1 |
| Fujii, N; Igarashi, N; Inoue, H; Matsuki, A; Nozawa, T; Sobajima, M; Suzuki, T | 1 |
| Akgullu, C; Aydinlar, A; Kazazoglu, AR; Ozdemir, B; Yilmaz, Y | 1 |
| Anstrom, KJ; Cowper, PA; Davidson-Ray, L; Knight, JD; Mark, DB | 1 |
| Martinez, DG | 1 |
| Bittner, V; Breazna, A; DeMicco, DA; Greten, H; Grundy, SM; Johnson, C; LaRosa, JC; Waters, DD | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM | 1 |
| Chiong, M; Lavandero, S; Llancaqueo, M; Noriega, V; Pennanen, C; Prieto, JC; Sánchez, MP | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 3 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Bonnet, J; Davignon, J; Martineau, P; McPherson, R; Nozza, A; Simoneau, D; Tedgui, A | 1 |
| Collins, RT; Hanna, B; Shaddy, RE | 1 |
| Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 2 |
| Corson, MA | 1 |
| Clementi, F; Di Luozzo, M; Luciani, G; Mango, R; Martuscelli, E; Mehta, JL; Pizzuto, F; Romeo, F; Trivisonno, A | 1 |
| Komiyama, N | 1 |
| Itoh, T; Maesawa, C; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Feldman, T; Koren, MJ; Mendes, RA | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 2 |
| Castilla-Guerra, L; Chaturvedi, S; Fernandez-Moreno, Mdel C; Jimenez-Hernandez, MD | 1 |
| Colonna, G; Di Sciascio, G; Gaspardone, A; Montinaro, A; Pasceri, V; Patti, G | 1 |
| Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q | 1 |
| Bertrand, OF; Cossette, M; Grégoire, J; Guertin, MC; Ibrahim, R; L'allier, PL; Larose, E; Rodés-Cabau, J; Tardif, JC | 1 |
| Liang, W; Lu, GP; Wu, CF; Yang, H; Yu, Q; Zhang, DD | 1 |
| Kirilmaz, A; Uzun, M; Yiğiner, O | 1 |
| Li, L; Meng, X; Qie, L; Wang, Y; Zhong, M | 1 |
| Cai, JZ; Feng, J; Ji, Q; Mei, YQ; Sun, YF; Wang, XS; Xie, SL; Zhou, YX | 1 |
| Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Abdul-Salam, VB; Boyle, JJ; Davies, AH; Edwards, RJ; Gillard, JH; Krishnan, U; Owen, DR; Ramrakha, P; Shalhoub, J; Tang, TY; Wilkins, MR | 1 |
| Colivicchi, F; Genovesi Ebert, A; Melina, G; Mocini, D; Santini, M; Strano, S; Tubaro, M; Uguccioni, M | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS | 1 |
| Fan, Y; Gan, RT; Han, W; Hao, JH; Huang, YL; Li, WM; Wang, Z; Yang, SS; Yu, JB | 1 |
| Borggrefe, M; Dempfle, CE; Hoffmeister, HM; Lang, S; Suselbeck, T; Swoboda, S; Szabo, S; Walter, T | 1 |
| Bahl, A; Khullar, M; Poduri, A; Sehrawat, BS; Sharma, Y; Talwar, KK | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Garg, N; Mittal, B; Srivastava, A; Srivastava, K | 1 |
| Achkouty, G; Aydanian, H; Azar, M; Azar, RR; Badaoui, G; Harb, S; Kassab, R; Sarkis, A | 1 |
| Clarkson, PM; Grimaldi, AS; Haller, RG; Hoffman, EP; Levine, BD; Parker, BA; Pescatello, LS; Thompson, PD; White, CM | 1 |
| Abrecht, L; Eshtehardi, P; Haeberli, A; Hess, OM; Meier, B; Schmidlin, K; Wenaweser, P; Windecker, S; Zwahlen, M | 1 |
| Arai, H; Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Aydin, C; Baysal, A; Bugra, O; Buyukbayrak, F; Caliskan, A; Erdem, H; Fedekar, A; Sasmazel, A; Sunar, H | 1 |
| Aksoy, N; Bas, M; Buyukhatıpoglu, H; Celik, H; Demirbag, R; Guntekin, U; Polat, M; Sezen, Y; Taskin, A; Yildiz, A | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Tedeschi, D; Toso, A | 1 |
| Aicher, A; Dimmeler, S; Fichtlscherer, S; Schmidt-Lucke, C; Schultheiss, HP; Tschöpe, C; Zeiher, AM | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Jensen, E; Leiter, LA; Shah, A; Tershakovec, AM | 1 |
| Ghilencea, L; Mario, CD; Moreno-Ambroj, C; Tyczyński, P; Witkowska, AB | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W | 1 |
| Kandic, I; Kutryk, MJ; Zhang, Q | 1 |
| Azar, M; Azar, RR; Badaoui, G; Kassab, R; Sarkis, A; Valentin, E | 1 |
| Patti, G | 1 |
| Bartos, J; Fischbein, MP; Itoh, S; Kimura, N; Palmer, O; Robbins, RC; Schrepfer, S; Stein, W; Velotta, J; Wang, X | 1 |
| Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 1 |
| Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T | 1 |
| Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vrabas, IS | 1 |
| Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Bendall, J; Casadei, B; Channon, KM; Demosthenous, M; Guzik, TJ; Hale, A; Leeson, P; Marinou, K; Paschalis, A; Psarros, C; Stefanadis, C; Tousoulis, D; Triantafyllou, C; Zhang, MH | 1 |
| Benit, E; Channon, KM; de Winter, RJ; den Dekker, WK; den Heijer, P; Duckers, HJ; Grisold, M; Hill, J; Houtgraaf, JH; Ligtenberg, E; Onuma, Y; Rensing, BJ; Rowland, SM; Serruys, PW; Silber, S; Teiger, E; Verheye, S; Wiemer, M; Wijns, W | 1 |
| Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Daida, H; Hibi, K; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Ieva, R; Montrone, D; Ruggiero, A | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Akar, AR; Arslan, Ö; Baran, Ç; Dalva, K; Dogan, A; Durdu, S; Gürman, G; Ocakoglu, G; Zaim, Ç | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K | 1 |
| Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A | 1 |
| Kawaguchi, R | 1 |
| Chapman, MJ | 1 |
| Drechsler, C; Hoffmann, MM; Krane, V; Wanner, C; Winkler, K | 1 |
| Nammas, W; Rifaie, O; Zahran, A | 1 |
| Sidorenko, BA; Zateĭshchikova, AA | 1 |
| Einecke, D | 4 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Villines, TC | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Hong, T; Huo, Y; Jia, J; Jiang, J; Li, J; Liu, P; Yu, R; Zhang, Y | 1 |
| Goto, SN; Iwata, K; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP | 1 |
| Angelica Merlini, P; Antonietta Demola, M; Ardissino, D; Francesca Notarangelo, M; Guidorossi, A; Marziliano, N; Pigazzani, F | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Chan, CW; Chan, KK; Chan, PH; Chan, RH; Hau, WK; Kong, SL; Lam, SC; Lam, YM; Lee, SW; Tam, FC; Tse, HF; Wong, MK | 1 |
| Kalil Filho, R; Kowatsch, I; Lario, FC; Mathias, W; Miname, MH; Ramires, JA; Santos, RD; Sbano, JC; Tsutsui, JM | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Binongo, JN; Corban, MT; Dhawan, SS; Eshtehardi, P; Golub, L; Krishnan, SK; McDaniel, MC; Quyyumi, AA; Raggi, P; Samady, H | 1 |
| Fujii, K; Masuyama, T | 1 |
| Yeboah, J | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC | 1 |
| Davutoglu, V; Ercan, S; Sari, I | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Adamova, IY; Afanasieva, OI; Atanesyan, RV; Ezhov, MV; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS; Utkina, EA | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Atanesyan, RV; Ezhov, MV; Il'ina, LN; Konovalov, GA; Pokrovsky, SN; Safarova, MS | 1 |
| Açil, T; Aksöyek, S; Atalar, E; Haznedaroglu, I; Kes, S; Ovünç, K; Ozer, N; Ozmen, F | 1 |
| Altamura, L; Chiariello, L; Gaspardone, A; Proietti, I; Skossyreva, O; Tomai, F; Versaci, F | 1 |
| Ashby, DT; Conditt, G; Dangas, G; Hirose, M | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Nissen, SE | 2 |
| Stein, EA | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Duffy, SJ; Gokce, N; Holbrook, M; Kahn, D; Keaney, JF; Palmisano, J; Thomas, S; Tomasian, D; Vita, JA | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Fathi, R; Haluska, B; Marwick, TH; Short, L | 1 |
| Arnesen, KE; Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Holm, AM; Pedersen, TR; Semb, AG; Torsvik, H; Waehre, T | 1 |
| Bednarz, B | 1 |
| Ceska, R; Kasalová, Z; Prázný, M; Skrha, J; Stulc, T; Vrablík, M | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Ishibashi, F; Mizuno, K; Okamatsu, K; Seimiya, K; Takano, M; Uemura, R; Yokoyama, S | 1 |
| Brown, WV; Moussa, M | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Blanco-Colio, LM; Egido, J; Osende, JI; Ruiz-Ortega, M | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Sacks, FM | 1 |
| Fang, CH; Li, JJ | 1 |
| Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Haug, T; Semb, AG; Smith, C; Tunheim, SH; Waehre, T; Yndestad, A | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Salam, AM | 1 |
| Bocksch, W; Fateh-Moghadam, S; Schartl, M | 1 |
| Düsing, R; Klose, G; Szucs, TD | 1 |
| Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW | 1 |
| Bubnova, MG | 1 |
| Hartmann, M; von Birgelen, C | 1 |
| Gawaz, M; Gorchakova, O; Joost, A; Kastrati, A; Mocz, A; Schömig, A; von Beckerath, N | 1 |
| Cannon, CP; Ray, KK | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Anderson, T; Boudreau, G; Buithieu, J; Chan, S; Charbonneau, F; Dorval, JF; Genest, J; Hutchison, S; Huynh, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Farmer, JA | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Andrews, TC; Carlson, W; Cole, H; Creager, MA; Frei, B; Johnstone, M; Kinlay, S; Lloyd-Jones, DM; Orav, J; Rubenstein, J; Selwyn, AP; Sopko, G; Stone, PH | 1 |
| Asztalos, BF; Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Bhatt, DL; Karha, J | 1 |
| Bigazzi, F; Bionda, A; Chella, E; Dal Pino, B; Puntoni, MR; Rossi, G; Sampietro, T; Sbrana, F | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Avorn, J | 1 |
| Arad, Y; Guerci, AD; Newstein, D; Roth, M; Spadaro, LA | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Courtney, BK; Fitzgerald, PJ; Koizumi, T; Komiyama, N; Komuro, I; Kuriyama, N; Nakayama, T; Nameki, M; Namikawa, S; Yokoyama, M | 1 |
| Cicero, AF; Gaddi, A | 1 |
| McKenney, JM | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Iwaniec, T; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Baller, D; Burchert, W; Gleichmann, U; Horstkotte, D; Pulawski, E; Wielepp, P | 1 |
| Shear, CL | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Błaszczyk, J; Ceglińiski, T; Grycewicz, J; Irzmańiski, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Boonstra, PW; Buikema, H; Morshuis, WJ; Nickenig, G; Plokker, HW; Six, AJ; van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ; Wassmann, S | 1 |
| Citkowitz, E | 1 |
| Bernard, D; De Backer, G; De Bacquer, D; De Buyzere, M; De Sutter, J; Jordaens, L; Langlois, M; Matthys, K; Tavernier, R; Van de Veire, NR | 1 |
| Crowe, T; Kapadia, S; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Alber, HF; Dichtl, W; Doerler, J; Frick, M; Pachinger, O; Schirmer, M; Stocker, EM; Suessenbacher, A; Weidinger, F | 1 |
| Kadzhaia, GV | 1 |
| Beck, T; Burgstahler, C; Heuschmid, M; Kopp, AF; Kuettner, A; Reimann, A; Schroeder, S | 1 |
| Achenbach, S; Budde, T; Buziashvili, Y; Erbel, R; Förster, A; Friedrich, G; Henein, M; Kerkhoff, G; Knollmann, F; Kukharchuk, V; Lahiri, A; Leischik, R; Moshage, W; Schartl, M; Schmermund, A; Siffert, W; Sinitsyn, V; Steinhagen-Thiessen, E; Vogt, A; Wiedeking, B | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Boon, NA; Burton, J; Cowell, SJ; Houslay, ES; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Albertsson, P; Grip, L; Karlsson, T; Levin, M; Solem, J; Wiklund, O | 1 |
| Biggi, A; Chauvie, S; Feola, M; La Scala, E; Papaleo, A; Rolfo, F; Uslenghi, E | 1 |
| Rosenson, RS | 1 |
| Gupta, R; Lakshmy, R; Maulik, SK; Naik, N; Narang, D; Thomas, MK | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Abdallah, MH; Dakik, HA; Karrowni, W | 1 |
| Arteaga Ll, A; Maiz G, A; Rigotti R, A | 1 |
| Boudoulas, H; Stefanadi, E; Stefanadis, C; Toutouzas, K; Tsiamis, E; Tsioufis, C; Vavuranakis, M | 1 |
| Erbel, R; Schmermund, A | 1 |
| Brack, J; Harriss, L; Krum, H; Ninnio, D; Skiba, M; Szramka, M; Windebank, E | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Sparks, DL; Stankovic, G | 1 |
| Beugels, I; de Winther, MP; Gijbels, MJ; Mensink, RP; Plat, J | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Miserez, AR; Romanens, MJ | 1 |
| Cheong, SS; Han, KH; Hong, MK; Jang, JS; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, CB; Park, DW; Park, SJ; Park, SW | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Gennimata, V; Ikonomidis, I; Kotsis, V; Lekakis, J; Pitiriga, V; Protogerou, A; Zakopoulos, N | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Mason, RP | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C | 1 |
| Nidorf, M; Thompson, PL | 1 |
| Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM | 1 |
| Tall, AR | 1 |
| Fukuda, N; Fukuda, Y; Morishita, S; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 1 |
| Guazzi, M; Guazzi, MD; Reina, G; Tumminello, G; Vicenzi, M | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
| Kaul, P | 1 |
| Kawamura, A; Mitsutake, R; Miura, S; Niimura, H; Okamura, K; Saku, K | 1 |
| Anderson, TJ; Buithieu, J; Chan, S; Charbonneau, F; Genest, J; Hutchison, S; Huyhn, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Funabashi, N; Komuro, I; Mikami, Y; Nakamura, K; Shiina, Y; Uehara, M | 1 |
| Caliskan, M; Ciftci, O; Erdogan, D; Gullu, H; Muderrisoglu, H; Topcu, S; Yildirir, A | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U | 1 |
| Calderaro, D; Caramelli, B; Gualandro, D; Yu, PC | 1 |
| Cieslik, G; Fedak, D; Galicka-Latala, D; Konduracka, E; Naskalski, J; Piwowarska, W; Rostoff, P; Sieradzki, J | 1 |
| Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Conover, CA; Harrington, SC; Henry, TD; MacDonald, H; Miedema, MD; Oberg, D; Schwartz, RS; Wilson, D | 1 |
| Acampa, M; Auteri, A; Bruni, F; Ciani, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Shaley, FM | 1 |
| Garner, J; Gould, KL; McLain, R; Sdringola, S; Zamarka, LG | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Bacarea, A; Dobreanu, D; Dobreanu, M; Fodor, A | 1 |
| Aukrust, P; Breland, UM; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Oie, E; Otterdal, K; Sandberg, WJ; Smith, C; Waehre, T; Yndestad, A | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A | 1 |
| Farmer, JA; Jones, PH | 1 |
| Liew, TV; Ray, KK | 1 |
| Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W | 1 |
| Koenig, W | 1 |
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| Bernstein, D; Chin, C; Lukito, SS; Perry, SB; Shek, J | 1 |
| Barter, P; Breazna, A; DeMicco, DA; Kastelein, JJ; LaRosa, JC; Shah, SJ; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortega, L; Ortego, M; Pérez, F; Tuñón, J | 1 |
| Kostner, KM | 1 |
| Rodrigues, M; Sinzinger, H | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortego, M; Tuñón, J | 1 |
| Caslake, M; Packard, C; Shepherd, J | 1 |
| Eisenberg, D | 1 |
| Brown, WV | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Campeau, L | 1 |
| Schwartz, JB | 1 |
| Libby, P | 1 |
| Hsue, PY; Waters, DD | 1 |
| Deedwania, P | 1 |
| Grundy, SM | 1 |
| Raggi, P | 1 |
| Erkelens, DW | 1 |
| Welty, FK | 1 |
| Harada-Shiba, M; Kawaguchi, A; Tsushima, M; Yamamoto, A | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
31 review(s) available for pyrroles and Coronary Artery Disease
| Article | Year |
|---|---|
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.
Topics: Apolipoproteins; Atorvastatin; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke | 2010 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Plaque, Atherosclerotic; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis | 2012 |
Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Lipoproteins, LDL; Pyrroles; Randomized Controlled Trials as Topic; Regional Blood Flow; Vasodilation | 2012 |
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
[Effects of statins on coronary artery disease. Review of the recent publications].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Topics: Atorvastatin; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Intravascular ultrasound assessment of coronary atherosclerosis and percutaneous interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Heptanoic Acids; Humans; Pyrroles; Stents; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2005 |
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins | 2006 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Intensive statin therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Platelets; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2008 |
[Aggressive therapy and combination therapy in severe hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
The role of small, dense low density lipoprotein (LDL): a new look.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pyrroles | 2000 |
Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Treatment Outcome | 2000 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
Lipid lowering and coronary bypass graft surgery.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Postoperative Period; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
Lipid-lowering medications: what the new guidelines and data mean to women.
Topics: Age Factors; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Practice Guidelines as Topic; Pyrroles; Triglycerides | 2001 |
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles | 2001 |
Apheresis technology for prevention and regression of atherosclerosis.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Plasmapheresis; Pyrroles; Treatment Outcome | 2001 |
168 trial(s) available for pyrroles and Coronary Artery Disease
| Article | Year |
|---|---|
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrroles; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Efficiency of statin treatment on EPC recruitment depends on baseline EPC titer and does not improve angiographic outcome in coronary artery disease patients treated with the Genous stent.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Demography; Endothelial Progenitor Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Pyrroles; Regression Analysis; Stents; Treatment Outcome | 2014 |
Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2013 |
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Endpoint Determination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Quinolines; Young Adult | 2013 |
Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.
Topics: Age of Onset; Atorvastatin; Biomarkers; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pedigree; Phenotype; Primary Prevention; Prospective Studies; Pyrroles; Republic of Korea; Time Factors; Treatment Outcome | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
Topics: Aged; Atorvastatin; Carrier Proteins; Case-Control Studies; Cell Line, Tumor; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Interleukin-18; Interleukin-1beta; Lipids; Male; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Quinolines; Ticlopidine | 2014 |
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
Topics: Atorvastatin; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; India; Male; Middle Aged; Pyrroles; Secondary Prevention; Treatment Outcome | 2013 |
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Topics: Atorvastatin; Body Weight; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Style; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Weight Loss | 2014 |
Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pyrroles; Research Design; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2014 |
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug Combinations; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reload.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Cardiac; Disease-Free Survival; Double-Blind Method; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Myocardial Infarction; Postoperative Complications; Preoperative Care; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
[Cardioprotective effect and mechanism of intensive lipid modulation on patients with coronary artery disease undergoing noncardiac surgery].
Topics: Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Brugada Syndrome; Cardiac Conduction System Disease; Coronary Artery Disease; Elective Surgical Procedures; Heart Conduction System; Heptanoic Acids; Humans; Lipids; Myocardial Infarction; Perioperative Period; Pyrroles | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarc
Topics: Anti-Arrhythmia Agents; Atorvastatin; Benzazepines; Biomarkers; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Emergencies; Femoral Neck Fractures; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Middle Aged; Myocardial Infarction; Orthopedic Procedures; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Research Design; Risk Factors; Severity of Illness Index; Tachycardia, Ventricular; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Tomography, Optical Coherence | 2014 |
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors | 2015 |
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol; Combined Modality Therapy; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; P-Selectin; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Elasticity; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors; Vascular Resistance | 2008 |
Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Hospital Costs; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Prospective Studies; Pyrroles; United States | 2008 |
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reoperation | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2008 |
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography | 2008 |
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Topics: Aged; Alleles; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Triglycerides; Trinucleotide Repeats | 2009 |
Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Count; Cells, Cultured; Cholesterol; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Stem Cells; Telomere | 2009 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Canada; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2010 |
Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Ultrasonography, Interventional | 2009 |
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; MicroRNAs; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Single-Blind Method; Statistics as Topic; Stem Cells | 2009 |
Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Confidence Intervals; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Pyrroles; Risk | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome | 2009 |
Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins A; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Niacin; Pyrroles | 2009 |
Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2009 |
[Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Metalloproteases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Young Adult | 2009 |
Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity.
Topics: Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2009 |
[Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting].
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk Factors | 2009 |
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr
Topics: Adult; Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Italy; Male; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2010 |
[Atorvastatin use and coronary flow reserve in patients with coronary slow flow].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fractional Flow Reserve, Myocardial; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acut
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Benzimidazoles; Benzoates; Cells, Cultured; Coronary Artery Disease; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MicroRNAs; Middle Aged; Pyrroles; Renin-Angiotensin System; Signal Transduction; Single-Blind Method; Telmisartan; Toll-Like Receptor 4 | 2010 |
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Creatine Kinase; Decision Trees; Double-Blind Method; Exercise Test; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isometric Contraction; Male; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Muscle Weakness; Muscle, Skeletal; Physical Endurance; Pyrroles; Research Design; Surveys and Questionnaires | 2010 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Prosthesis Design; Pyrroles; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
The effect of statin therapy on stimulation of endothelium-derived nitric oxide before and after coronary artery bypass surgery.
Topics: Aged; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Intraoperative Period; Male; Middle Aged; Nitric Oxide; Nitroglycerin; Postoperative Care; Preoperative Care; Pyrroles; Vasodilator Agents | 2010 |
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Lupus Atherosclerosis Prevention Study (LAPS).
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2011 |
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles; Treatment Outcome | 2011 |
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Echocardiography; Exercise; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Smoking; Sulfonamides; Ubiquinone | 2011 |
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Prospective Studies; Pyrroles; Regression Analysis; Risk Factors; Risk Reduction Behavior; Serpins | 2011 |
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease.
Topics: Aged; Analysis of Variance; Angiogenic Proteins; Angiopoietin-2; Atorvastatin; Biomarkers; Coronary Artery Disease; Down-Regulation; Female; Hepatocyte Growth Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leptin; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Niacin; Plasminogen Activator Inhibitor 1; Pyrroles; Treatment Outcome; Tunica Intima | 2011 |
Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling.
Topics: Aged; Atorvastatin; Biological Availability; Biopterins; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxidative Coupling; Oxygen; Pyrroles; Superoxides | 2011 |
Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Cell Movement; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Disease-Free Survival; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Stem Cells; Stents; Treatment Outcome | 2011 |
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in ac
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; Chi-Square Distribution; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; Quinolines; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal.
Topics: Aged; Atorvastatin; Cell Line; Coronary Artery Disease; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Toll-Like Receptor 4 | 2012 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Coronary Artery Bypass; Coronary Artery Disease; Endothelium; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Preoperative Period; Pyrroles; Stem Cell Transplantation; Treatment Outcome; Troponin I | 2012 |
Effect of two intensive statin regimens on progression of coronary disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2011 |
Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
Topics: Adiponectin; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Biomarkers; Blood Pressure; Brachial Artery; Cholesterol; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography | 2011 |
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Area Under Curve; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Renal Dialysis; Risk Factors | 2012 |
Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Single-Blind Method; Treatment Outcome | 2012 |
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional | 2012 |
MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
Topics: Aged; Atorvastatin; Cell Count; Cell Movement; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Longevity; Male; MicroRNAs; Oxidative Stress; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; Sirtuin 1; Sulfonamides; Transfection | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design.
Topics: Angioplasty, Balloon, Coronary; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; China; Coronary Artery Disease; Creatine; Creatine Kinase, MB Form; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Time Factors; Treatment Outcome; Troponin I | 2012 |
Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Time Factors; Treatment Outcome; Triglycerides | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Exercise; Fluorobenzenes; Heptanoic Acids; Humans; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness | 2012 |
Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Myocardial Perfusion Imaging; Pyrroles; Treatment Outcome | 2013 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Microvessels; Middle Aged; Phenotype; Pilot Projects; Pyrroles; Regional Blood Flow; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional; Vascular Resistance | 2012 |
Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrroles | 2013 |
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Russia; Time Factors; Treatment Outcome | 2013 |
Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Russia; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Fatty Acids; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; L-Selectin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Incidence; Italy; Male; Middle Aged; Postoperative Care; Preoperative Care; Prospective Studies; Pyrroles; Stents; Survival Analysis; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Muscle, Smooth, Vascular; Nitroglycerin; Pyrroles; Syndrome; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2003 |
A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention.
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Echocardiography, Stress; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Surveys and Questionnaires; Vascular Resistance | 2003 |
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; Chemokines; Coronary Artery Disease; Dose-Response Relationship, Drug; Down-Regulation; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, Chemokine; RNA, Messenger; Simvastatin; Time Factors | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Color; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Topics: Angina Pectoris; Angina, Unstable; Atorvastatin; Coronary Artery Disease; Cross-Sectional Studies; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Effects of lipid-lowering therapy on coronary artery remodeling.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Pyrroles; Statistics as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Topics: Angina Pectoris; Antioxidants; Ascorbic Acid; Atorvastatin; Coronary Artery Disease; Diet Therapy; Dose-Response Relationship, Drug; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Myocardial Ischemia; Pyrroles; Vasomotor System; Vitamin E | 2005 |
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
Topics: Aged; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Aspirin; Atorvastatin; Calcinosis; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Tomography, X-Ray Computed | 2005 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Comorbidity; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Radio Waves; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Treatment Outcome; Vasodilation; Ventricular Dysfunction, Left | 2005 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on antioxidative enzymatic activity].
Topics: Adult; Antioxidants; Atorvastatin; Coronary Artery Disease; Erythrocytes; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
Topics: Aged; Angiotensin II; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Male; Mammary Arteries; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Vasodilation | 2005 |
Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Belgium; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Greece; Heptanoic Acids; Humans; Inflammation; Inflammation Mediators; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prevalence; Pyrroles; Research Design; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation | 2006 |
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; T-Lymphocyte Subsets | 2006 |
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
Topics: Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Free Radical Scavengers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.
Topics: Adult; Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Tomography, Spiral Computed; Treatment Failure | 2006 |
Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment.
Topics: Adult; Aged; Angina Pectoris; Apolipoprotein A-I; Atherectomy, Coronary; Atorvastatin; Biomarkers; Collagen; Combined Modality Therapy; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunity, Cellular; Inflammation Mediators; Lipids; Lymphocyte Count; Male; Middle Aged; Pyrroles; T-Lymphocytes | 2006 |
Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Thiobarbituric Acid Reactive Substances | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment.
Topics: Aged; Atorvastatin; Body Temperature; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Pyrroles; Thermography | 2007 |
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Autonomic Nervous System; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles | 2007 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cognition; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Neuropsychological Tests; Placebos; Prognosis; Pyrroles; Vasculitis | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
Topics: Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Colchicine; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Treatment Outcome | 2007 |
Effect of torcetrapib on the progression of coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional | 2007 |
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Time Factors; Vasodilation | 2008 |
Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Echocardiography; Exercise Test; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Consumption; Pyrroles | 2007 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX).
Topics: Adult; Aged; Amlodipine; Apolipoproteins B; Atorvastatin; Biomarkers; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography; Vasodilation | 2008 |
Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2007 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Artery Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Antagonists; Male; Middle Aged; Pioglitazone; Pyrroles; Thiazolidinediones; Treatment Outcome | 2007 |
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Vasodilation; von Willebrand Factor | 2008 |
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2007 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2008 |
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E | 2008 |
A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Double-Blind Method; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Ischemia; Positron-Emission Tomography; Prospective Studies; Pyrroles | 2008 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Pyrroles; Risk; Triglycerides | 2008 |
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors | 2008 |
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Female; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
131 other study(ies) available for pyrroles and Coronary Artery Disease
| Article | Year |
|---|---|
[Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting].
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2019 |
Pharmacological interactions: the next frontier?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrroles; Ticlopidine | 2013 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
Topics: Atorvastatin; Atrial Fibrillation; Comorbidity; Coronary Artery Bypass; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Premedication; Prevalence; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
[Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
Topics: Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2013 |
[Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Promoter Regions, Genetic; Pyrroles; Treatment Outcome | 2013 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients.
Topics: Adiponectin; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Combined Modality Therapy; Coronary Artery Disease; Exercise Therapy; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Molecular Weight; Multivariate Analysis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pyrroles; Treatment Outcome | 2014 |
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
Women are from SATURN and men are from an ASTEROID: deciphering the REVERSAL of coronary atheroma.
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Sulfonamides; Ultrasonography | 2014 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
Topics: Atorvastatin; China; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Survival Rate | 2014 |
Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Intriguing Off-Target Effects of Ezetimibe.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2015 |
Reply: Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Getting What the Guidelines Stated Matters.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
Reply: Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: CHOICE Trial Results.
Topics: Azetidines; Coronary Artery Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles | 2016 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Statins, regulatory T cells, and pediatric graft coronary artery disease.
Topics: Atorvastatin; Child; Coronary Artery Disease; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
Assessment of regional systolic and diastolic functions affected by atorvastatin in coronary artery disease using tissue Doppler imaging.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Diastole; Female; Heart Ventricles; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Systole; Ultrasonography, Doppler; Ventricular Function, Left | 2008 |
Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Coronary Artery Disease; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Natriuretic Peptide, Brain; Oxidative Stress; Pyrroles; Treatment Outcome; Ubiquinone | 2008 |
Binder wars.
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke | 2008 |
Letter to editor in response to "Prevention of pediatric graft coronary artery disease: atorvastatin", by Chin et al.
Topics: Atorvastatin; Child; Coronary Artery Disease; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Period; Pyrroles | 2009 |
Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Topics: Atorvastatin; Benzaldehydes; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oximes; Phospholipases A2, Secretory; Pyrroles | 2009 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Necrosis; Pilot Projects; Pioglitazone; Prospective Studies; Pyrroles; Registries; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Statin-induced structural changes in coronary plaques evaluated by intracoronary imaging.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Ultrasonography, Interventional | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Heptanoic Acids; Humans; Ischemic Attack, Transient; Outcome Assessment, Health Care; Pyrroles; Stroke; Treatment Outcome | 2009 |
The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
Topics: Adult; Alanine Transaminase; Atorvastatin; Contraindications; Coronary Artery Disease; Fatty Liver; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pyrroles | 2009 |
Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis.
Topics: Aged; Angina Pectoris; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Male; Middle Aged; Muramidase; Predictive Value of Tests; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Up-Regulation | 2010 |
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Randomized Controlled Trials as Topic; Thrombin | 2010 |
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Topics: Adult; Alleles; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol 7-alpha-Hydroxylase; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Polymorphism, Single Nucleotide; Pyrroles; Triglycerides | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity.
Topics: Aged; Antioxidants; Atorvastatin; Ceruloplasmin; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidants; Pyrroles | 2010 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kidney Diseases; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Biomarkers; Coronary Artery Disease; Endothelial Cells; Female; Flow Cytometry; Hematology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Long term observation of thin-cap fibroatheroma by optical coherence tomography.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Necrosis; Pyrroles; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2010 |
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MicroRNAs; Neovascularization, Physiologic; Pyrroles; Stem Cells | 2011 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Evidence-Based Medicine; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Myocardial Infarction; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Prevention of transplant coronary artery disease by prenylation inhibitors.
Topics: Animals; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Coronary Artery Disease; Diphosphonates; Genes, MHC Class II; Graft Survival; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Male; Mice; Mice, Inbred C57BL; Models, Biological; Muscle, Smooth; Polyenes; Polyunsaturated Alkamides; Prenylation; Pyridines; Pyrroles; Signal Transduction; Time Factors; Transplantation, Heterotopic; Tricarboxylic Acids | 2011 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed | 2011 |
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin.
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Radiography; Time Factors; Treatment Outcome; Young Adult | 2012 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
[Atorvastatin for secondary prevention in patients with coronary artery disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Pyrroles; Secondary Prevention | 2011 |
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2011 |
Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it?
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Vascular Calcification | 2012 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
[In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2012 |
Genetic predisposition to atorvastatin-induced myopathy: a case report.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles | 2012 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles | 2013 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
Dramatic regression of three-vessel disease under statin treatment in patients with stable angina pectoris.
Topics: Angina, Stable; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
[Maintaining the full benefit of statins. Therapy start 10 years earlier?].
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2002 |
Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD.
Topics: Adult; Aspirin; Atorvastatin; Cardiac Catheterization; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Isosorbide; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2002 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Pyrroles; Skin | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Aggressive lipid-lowering regimen halts CHD progression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
[First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Time Factors; Ultrasonography, Interventional | 2003 |
High-intensity statin treatment for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pravastatin; Pyrroles; Risk Factors; Ultrasonography, Interventional | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
[Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Effect of withdrawal of statin on C-reactive protein.
Topics: Aged; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Risk Factors; Substance Withdrawal Syndrome | 2004 |
[Atorvastatin: lipid lowering activity, pleiotropic properties and efficacy in prevention of atherosclerosis and coronary heart disease].
Topics: Atherosclerosis; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Pyrroles; Simvastatin; Stents; Ticlopidine | 2004 |
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2005 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Coronary Artery Disease; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Phospholipases A; Phospholipases A2; Placebos; Postprandial Period; Pyrroles | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Complement C3; Complement C4; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunity, Cellular; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Pyrroles; Up-Regulation | 2005 |
Torcetrapib and atorvastatin--should marketing drive the research agenda?
Topics: Anticholesteremic Agents; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Approval; Drug Combinations; Drug Industry; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing; Molecular Structure; Pyrroles; Quinolines; Research Design; United States; United States Food and Drug Administration | 2005 |
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies?
Topics: Atorvastatin; Coronary Artery Disease; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome Assessment, Health Care; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
Topics: Alleles; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Coronary Artery Disease; Fibrin Fibrinogen Degradation Products; Genotype; Hemostasis; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Pyrroles; Quinapril; Risk; Tetrahydroisoquinolines; Time Factors | 2005 |
Torcetrapib and atorvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Combinations; Drug Industry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines | 2005 |
Statin comparisons in controlled clinical trials.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Controlled Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Phospholipases A; Postprandial Period; Pyrroles | 2005 |
Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2005 |
[Fluctuation of C-reactive protein levels in acute coronary syndrome].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2005 |
Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
Topics: Aspirin; Atorvastatin; Carotid Stenosis; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Radiography | 2006 |
Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Profound regression of coronary atherosclerosis with statins.
Topics: Atorvastatin; Cholesterol; Coronary Angiography; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2006 |
Letter by Schmermund and Erbel regarding article, "Coronary artery calcium: should we rely on this surrogate marker?".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium; Coronary Artery Disease; Coronary Vessels; Disease Progression; Heptanoic Acids; Humans; Predictive Value of Tests; Prognosis; Pyrroles; Risk Factors | 2006 |
Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Female; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phytosterols; Pyrroles; Receptors, LDL; Sitosterols | 2006 |
Letter by Romanens and Miserez regarding article, "Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sample Size | 2006 |
Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Databases as Topic; Elastic Tissue; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Simvastatin; Tunica Media; Ultrasonography, Interventional | 2006 |
Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link?
Topics: Adult; Aged; Arteries; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Constriction, Pathologic; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Smoking; Vascular Resistance | 2006 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
CETP inhibitors to increase HDL cholesterol levels.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Successful intensive lipid-lowering therapy using atorvastatin stabilizes coronary artery plaque as assessed by multi-detector row computed tomography.
Topics: Adult; Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Stenosis; Follow-Up Studies; Heptanoic Acids; Humans; Male; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Quantitative effect of atorvastatin on size and content of non-calcified plaques of coronary arteries 1 year after atorvastatin treatment by multislice computed tomography.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Tomography, Spiral Computed | 2008 |
Preoperative lipid-lowering therapy on postoperative outcome.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Heptanoic Acids; Humans; Postoperative Complications; Preoperative Care; Pyrroles; Survival Analysis; Treatment Outcome | 2007 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Integrin alpha Chains; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pyrroles; T-Lymphocytes | 2007 |
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Topics: Aged; Atorvastatin; Case-Control Studies; Cells, Cultured; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; Coronary Artery Disease; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Receptors, Scavenger; Simvastatin | 2008 |
Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Inflammation; Pyrroles | 2008 |
Prevention of pediatric graft coronary artery disease: atorvastatin.
Topics: Angiography; Atorvastatin; Case-Control Studies; Child; Coronary Artery Disease; Female; Follow-Up Studies; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Pyrroles; Time Factors; Treatment Outcome | 2008 |
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Topics: Animals; Atorvastatin; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Evaluation Studies as Topic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation; Tunica Intima | 1998 |
Atorvastatin and fibrinogen--a small subgroup shows extreme response.
Topics: Adult; Aged; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome | 1999 |
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Topics: Animals; Atorvastatin; Base Sequence; Blotting, Western; Cells, Cultured; Chemokines; Coronary Artery Disease; Coronary Vessels; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Molecular Sequence Data; Monocytes; Muscle, Smooth, Vascular; NF-kappa B; Polymerase Chain Reaction; Pyrroles; Rats; Reproducibility of Results; Sensitivity and Specificity | 1999 |
[Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Risk Factors; Survival Rate | 2001 |
What have we learned about the biology of atherosclerosis? The role of inflammation.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Coronary Artery Disease; Coronary Stenosis; Heptanoic Acids; Humans; Inflammation Mediators; Pyrroles; Rabbits | 2001 |
Global risk assessment in the presymptomatic patient.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Critical Pathways; Family Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Life Style; Mass Screening; Pyrroles; Risk Assessment | 2001 |
The use of electron-beam computed tomography as a tool for primary prevention.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Mass Screening; Middle Aged; Myocardial Infarction; Pyrroles; Tomography, X-Ray Computed | 2001 |
Insulin resistance syndrome and type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate | 2001 |
Women and cardiovascular risk.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Sex Factors; Survival Rate | 2001 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |